The Asian Network of People who Use Drugs (ANPUD) has grave concerns based on the updated 2016 guidelines and recommends the actions that governments in Asia need to prioritize. Please read the full press release and share it with all the relevant stakeholders.

DDW 2015: Sofosbuvir + Daclatasvir for 12 Weeks Cures Most HIV/HCV Coinfected Patients

Kenneth Sherman from the University of Cincinnati presented findings from the Phase 3 ALLY-2 trial, which evaluated Gilead Sciences' nucleotide polymerase inhibitor sofosbuvir plus Bristol-Myers Squibb's NS5A inhibitor daclatasvir without ribavirin.
Daclatasvir is available in Europe and Japan and is currently awaiting U.S. Food and Drug Administration approval. Gilead's Harvoni coformulation contains sofosbuvir plus its own NS5A inhibitor, ledipasvir. Unlike ledipasvir, which is active against genotype 1, daclatasvir is more pangenotypic, meaning it works against multiple HCV genotypes.